ThyroSeq ® V2.0 Molecular Testing: A Cost-Effective Approach for the Evaluation of Indeterminate Thyroid Nodules
Approximately 15 to 30% of thyroid nodules have indeterminate cytology. Many of these nodules are treated surgically, but only 5 to 30% are malignant. Molecular testing can further narrow the risk of malignancy of these nodules. Our objective was to assess the cost effectiveness of ThyroSeq V2.0 com...
Gespeichert in:
| Veröffentlicht in: | Endocrine practice 2018-09, Vol.24 (9), p.780-788 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 788 |
|---|---|
| container_issue | 9 |
| container_start_page | 780 |
| container_title | Endocrine practice |
| container_volume | 24 |
| creator | Rivas, Ana Marcella Nassar, Aziza Zhang, Jun Casler, John D Chindris, Ana Maria Smallridge, Robert Bernet, Victor |
| description | Approximately 15 to 30% of thyroid nodules have indeterminate cytology. Many of these nodules are treated surgically, but only 5 to 30% are malignant. Molecular testing can further narrow the risk of malignancy of these nodules. Our objective was to assess the cost effectiveness of ThyroSeq
V2.0 compared to diagnostic thyroidectomy for the evaluation of indeterminate nodules.
Cytology and histopathology slides of Bethesda category III and IV (suspicious for follicular neoplasia [SFN]) nodules obtained between January 1, 2014 and November 30, 2016 were re-reviewed by 2 endocrine cytopathologists. Costs for a diagnostic approach using ThyroSeq
were calculated and compared to those of diagnostic thyroidectomy.
We included 8 Bethesda category III nodules that underwent ThyroSeq
and 8 that underwent diagnostic surgery. Of those submitted for ThyroSeq
, 4 were positive for mutations and underwent thyroid surgery. The average cost per nodule evaluated was $14,669 using ThyroSeq
, compared to $23,338 for diagnostic thyroid surgery. The cost per thyroid cancer case detected was $58,674 using ThyroSeq
compared to $62,233 for diagnostic thyroid surgery. We included 13 nodules Bethesda category IV that underwent ThyroSeq
and 11 that underwent diagnostic surgery. Of those submitted for ThyroSeq
, 6 were positive for mutation and underwent thyroid surgery. The average costs per nodule evaluated were $14,641 using ThyroSeq
and $24,345 using diagnostic thyroidectomy. The cost per thyroid cancer case detected was $31,721 when using ThyroSeq
compared to $53,560 for diagnostic thyroidectomy.
The use of ThyroSeq® in our institution is cost effective compared to diagnostic thyroid surgery for the evaluation of Bethesda categories III and IV (SFN) nodules.
FNA = fine-needle aspiration; GEC = gene expression classifier; NIFTP = noninvasive follicular thyroid neoplasm with papillary-like nuclear features; PTC = papillary thyroid cancer; SFN = suspicious for follicular neoplasia. |
| doi_str_mv | 10.4158/EP-2018-0212 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2084914802</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2084914802</sourcerecordid><originalsourceid>FETCH-LOGICAL-c249t-d0e24357903d396c445d4c04b3536777e880fc67f27a91ecef9cfc5a0e29fa083</originalsourceid><addsrcrecordid>eNpdkctOHDEQRa0IFAjJLmtkiQ2LNCk_etpmNxo1DwkSpEyi7CzjLjONetozdjfS_FQ-Il-Gh9eCVdXiVNWtewn5yuBEslJ9r28KDkwVwBn_QPaZFrLgEsRO7ksBhdLs7x75lNI9AAfN1EeyJwCUnFTVPlnPF5sYfuGa_v9H__AToNehQzd2NtI5pqHt707plM5CGorae3RD-4B0ulrFYN2C-hDpsEBaP9hutEMbeho8vewbHDAu294OSJ8utA39EZqxw_SZ7HrbJfzyUg_I77N6Prsorn6eX86mV4XjUg9FA8ilKCsNohF64qQsG-lA3opSZOUVKgXeTSrPK6sZOvTaeVfaPKa9BSUOyPHz3ix1PeZXzLJNDrvO9hjGZHi2QDOpgGf06B16H8bYZ3UmmwoMdFVBpr49Uy6GlCJ6s4rt0saNYWC2UZj6xmyjMNsoMn74snS8XWLzBr96Lx4BawCC_Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2120109770</pqid></control><display><type>article</type><title>ThyroSeq ® V2.0 Molecular Testing: A Cost-Effective Approach for the Evaluation of Indeterminate Thyroid Nodules</title><source>MEDLINE</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><creator>Rivas, Ana Marcella ; Nassar, Aziza ; Zhang, Jun ; Casler, John D ; Chindris, Ana Maria ; Smallridge, Robert ; Bernet, Victor</creator><creatorcontrib>Rivas, Ana Marcella ; Nassar, Aziza ; Zhang, Jun ; Casler, John D ; Chindris, Ana Maria ; Smallridge, Robert ; Bernet, Victor</creatorcontrib><description>Approximately 15 to 30% of thyroid nodules have indeterminate cytology. Many of these nodules are treated surgically, but only 5 to 30% are malignant. Molecular testing can further narrow the risk of malignancy of these nodules. Our objective was to assess the cost effectiveness of ThyroSeq
V2.0 compared to diagnostic thyroidectomy for the evaluation of indeterminate nodules.
Cytology and histopathology slides of Bethesda category III and IV (suspicious for follicular neoplasia [SFN]) nodules obtained between January 1, 2014 and November 30, 2016 were re-reviewed by 2 endocrine cytopathologists. Costs for a diagnostic approach using ThyroSeq
were calculated and compared to those of diagnostic thyroidectomy.
We included 8 Bethesda category III nodules that underwent ThyroSeq
and 8 that underwent diagnostic surgery. Of those submitted for ThyroSeq
, 4 were positive for mutations and underwent thyroid surgery. The average cost per nodule evaluated was $14,669 using ThyroSeq
, compared to $23,338 for diagnostic thyroid surgery. The cost per thyroid cancer case detected was $58,674 using ThyroSeq
compared to $62,233 for diagnostic thyroid surgery. We included 13 nodules Bethesda category IV that underwent ThyroSeq
and 11 that underwent diagnostic surgery. Of those submitted for ThyroSeq
, 6 were positive for mutation and underwent thyroid surgery. The average costs per nodule evaluated were $14,641 using ThyroSeq
and $24,345 using diagnostic thyroidectomy. The cost per thyroid cancer case detected was $31,721 when using ThyroSeq
compared to $53,560 for diagnostic thyroidectomy.
The use of ThyroSeq® in our institution is cost effective compared to diagnostic thyroid surgery for the evaluation of Bethesda categories III and IV (SFN) nodules.
FNA = fine-needle aspiration; GEC = gene expression classifier; NIFTP = noninvasive follicular thyroid neoplasm with papillary-like nuclear features; PTC = papillary thyroid cancer; SFN = suspicious for follicular neoplasia.</description><identifier>ISSN: 1530-891X</identifier><identifier>EISSN: 1934-2403</identifier><identifier>DOI: 10.4158/EP-2018-0212</identifier><identifier>PMID: 30084677</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>Biopsy, Fine-Needle ; Cellular biology ; Cost analysis ; Cost-Benefit Analysis ; Gene expression ; Health Care Costs ; Histopathology ; Humans ; Medical diagnosis ; Mutation ; Retrospective Studies ; Surgery ; Thyroid cancer ; Thyroid Nodule - diagnosis ; Thyroid Nodule - genetics ; Thyroid Nodule - surgery ; Thyroidectomy ; Tumors</subject><ispartof>Endocrine practice, 2018-09, Vol.24 (9), p.780-788</ispartof><rights>Copyright Allen Press Publishing Services Sep 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c249t-d0e24357903d396c445d4c04b3536777e880fc67f27a91ecef9cfc5a0e29fa083</citedby><cites>FETCH-LOGICAL-c249t-d0e24357903d396c445d4c04b3536777e880fc67f27a91ecef9cfc5a0e29fa083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2120109770?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30084677$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rivas, Ana Marcella</creatorcontrib><creatorcontrib>Nassar, Aziza</creatorcontrib><creatorcontrib>Zhang, Jun</creatorcontrib><creatorcontrib>Casler, John D</creatorcontrib><creatorcontrib>Chindris, Ana Maria</creatorcontrib><creatorcontrib>Smallridge, Robert</creatorcontrib><creatorcontrib>Bernet, Victor</creatorcontrib><title>ThyroSeq ® V2.0 Molecular Testing: A Cost-Effective Approach for the Evaluation of Indeterminate Thyroid Nodules</title><title>Endocrine practice</title><addtitle>Endocr Pract</addtitle><description>Approximately 15 to 30% of thyroid nodules have indeterminate cytology. Many of these nodules are treated surgically, but only 5 to 30% are malignant. Molecular testing can further narrow the risk of malignancy of these nodules. Our objective was to assess the cost effectiveness of ThyroSeq
V2.0 compared to diagnostic thyroidectomy for the evaluation of indeterminate nodules.
Cytology and histopathology slides of Bethesda category III and IV (suspicious for follicular neoplasia [SFN]) nodules obtained between January 1, 2014 and November 30, 2016 were re-reviewed by 2 endocrine cytopathologists. Costs for a diagnostic approach using ThyroSeq
were calculated and compared to those of diagnostic thyroidectomy.
We included 8 Bethesda category III nodules that underwent ThyroSeq
and 8 that underwent diagnostic surgery. Of those submitted for ThyroSeq
, 4 were positive for mutations and underwent thyroid surgery. The average cost per nodule evaluated was $14,669 using ThyroSeq
, compared to $23,338 for diagnostic thyroid surgery. The cost per thyroid cancer case detected was $58,674 using ThyroSeq
compared to $62,233 for diagnostic thyroid surgery. We included 13 nodules Bethesda category IV that underwent ThyroSeq
and 11 that underwent diagnostic surgery. Of those submitted for ThyroSeq
, 6 were positive for mutation and underwent thyroid surgery. The average costs per nodule evaluated were $14,641 using ThyroSeq
and $24,345 using diagnostic thyroidectomy. The cost per thyroid cancer case detected was $31,721 when using ThyroSeq
compared to $53,560 for diagnostic thyroidectomy.
The use of ThyroSeq® in our institution is cost effective compared to diagnostic thyroid surgery for the evaluation of Bethesda categories III and IV (SFN) nodules.
FNA = fine-needle aspiration; GEC = gene expression classifier; NIFTP = noninvasive follicular thyroid neoplasm with papillary-like nuclear features; PTC = papillary thyroid cancer; SFN = suspicious for follicular neoplasia.</description><subject>Biopsy, Fine-Needle</subject><subject>Cellular biology</subject><subject>Cost analysis</subject><subject>Cost-Benefit Analysis</subject><subject>Gene expression</subject><subject>Health Care Costs</subject><subject>Histopathology</subject><subject>Humans</subject><subject>Medical diagnosis</subject><subject>Mutation</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Thyroid cancer</subject><subject>Thyroid Nodule - diagnosis</subject><subject>Thyroid Nodule - genetics</subject><subject>Thyroid Nodule - surgery</subject><subject>Thyroidectomy</subject><subject>Tumors</subject><issn>1530-891X</issn><issn>1934-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkctOHDEQRa0IFAjJLmtkiQ2LNCk_etpmNxo1DwkSpEyi7CzjLjONetozdjfS_FQ-Il-Gh9eCVdXiVNWtewn5yuBEslJ9r28KDkwVwBn_QPaZFrLgEsRO7ksBhdLs7x75lNI9AAfN1EeyJwCUnFTVPlnPF5sYfuGa_v9H__AToNehQzd2NtI5pqHt707plM5CGorae3RD-4B0ulrFYN2C-hDpsEBaP9hutEMbeho8vewbHDAu294OSJ8utA39EZqxw_SZ7HrbJfzyUg_I77N6Prsorn6eX86mV4XjUg9FA8ilKCsNohF64qQsG-lA3opSZOUVKgXeTSrPK6sZOvTaeVfaPKa9BSUOyPHz3ix1PeZXzLJNDrvO9hjGZHi2QDOpgGf06B16H8bYZ3UmmwoMdFVBpr49Uy6GlCJ6s4rt0saNYWC2UZj6xmyjMNsoMn74snS8XWLzBr96Lx4BawCC_Q</recordid><startdate>201809</startdate><enddate>201809</enddate><creator>Rivas, Ana Marcella</creator><creator>Nassar, Aziza</creator><creator>Zhang, Jun</creator><creator>Casler, John D</creator><creator>Chindris, Ana Maria</creator><creator>Smallridge, Robert</creator><creator>Bernet, Victor</creator><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>201809</creationdate><title>ThyroSeq ® V2.0 Molecular Testing: A Cost-Effective Approach for the Evaluation of Indeterminate Thyroid Nodules</title><author>Rivas, Ana Marcella ; Nassar, Aziza ; Zhang, Jun ; Casler, John D ; Chindris, Ana Maria ; Smallridge, Robert ; Bernet, Victor</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c249t-d0e24357903d396c445d4c04b3536777e880fc67f27a91ecef9cfc5a0e29fa083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biopsy, Fine-Needle</topic><topic>Cellular biology</topic><topic>Cost analysis</topic><topic>Cost-Benefit Analysis</topic><topic>Gene expression</topic><topic>Health Care Costs</topic><topic>Histopathology</topic><topic>Humans</topic><topic>Medical diagnosis</topic><topic>Mutation</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Thyroid cancer</topic><topic>Thyroid Nodule - diagnosis</topic><topic>Thyroid Nodule - genetics</topic><topic>Thyroid Nodule - surgery</topic><topic>Thyroidectomy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rivas, Ana Marcella</creatorcontrib><creatorcontrib>Nassar, Aziza</creatorcontrib><creatorcontrib>Zhang, Jun</creatorcontrib><creatorcontrib>Casler, John D</creatorcontrib><creatorcontrib>Chindris, Ana Maria</creatorcontrib><creatorcontrib>Smallridge, Robert</creatorcontrib><creatorcontrib>Bernet, Victor</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Endocrine practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rivas, Ana Marcella</au><au>Nassar, Aziza</au><au>Zhang, Jun</au><au>Casler, John D</au><au>Chindris, Ana Maria</au><au>Smallridge, Robert</au><au>Bernet, Victor</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ThyroSeq ® V2.0 Molecular Testing: A Cost-Effective Approach for the Evaluation of Indeterminate Thyroid Nodules</atitle><jtitle>Endocrine practice</jtitle><addtitle>Endocr Pract</addtitle><date>2018-09</date><risdate>2018</risdate><volume>24</volume><issue>9</issue><spage>780</spage><epage>788</epage><pages>780-788</pages><issn>1530-891X</issn><eissn>1934-2403</eissn><abstract>Approximately 15 to 30% of thyroid nodules have indeterminate cytology. Many of these nodules are treated surgically, but only 5 to 30% are malignant. Molecular testing can further narrow the risk of malignancy of these nodules. Our objective was to assess the cost effectiveness of ThyroSeq
V2.0 compared to diagnostic thyroidectomy for the evaluation of indeterminate nodules.
Cytology and histopathology slides of Bethesda category III and IV (suspicious for follicular neoplasia [SFN]) nodules obtained between January 1, 2014 and November 30, 2016 were re-reviewed by 2 endocrine cytopathologists. Costs for a diagnostic approach using ThyroSeq
were calculated and compared to those of diagnostic thyroidectomy.
We included 8 Bethesda category III nodules that underwent ThyroSeq
and 8 that underwent diagnostic surgery. Of those submitted for ThyroSeq
, 4 were positive for mutations and underwent thyroid surgery. The average cost per nodule evaluated was $14,669 using ThyroSeq
, compared to $23,338 for diagnostic thyroid surgery. The cost per thyroid cancer case detected was $58,674 using ThyroSeq
compared to $62,233 for diagnostic thyroid surgery. We included 13 nodules Bethesda category IV that underwent ThyroSeq
and 11 that underwent diagnostic surgery. Of those submitted for ThyroSeq
, 6 were positive for mutation and underwent thyroid surgery. The average costs per nodule evaluated were $14,641 using ThyroSeq
and $24,345 using diagnostic thyroidectomy. The cost per thyroid cancer case detected was $31,721 when using ThyroSeq
compared to $53,560 for diagnostic thyroidectomy.
The use of ThyroSeq® in our institution is cost effective compared to diagnostic thyroid surgery for the evaluation of Bethesda categories III and IV (SFN) nodules.
FNA = fine-needle aspiration; GEC = gene expression classifier; NIFTP = noninvasive follicular thyroid neoplasm with papillary-like nuclear features; PTC = papillary thyroid cancer; SFN = suspicious for follicular neoplasia.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>30084677</pmid><doi>10.4158/EP-2018-0212</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1530-891X |
| ispartof | Endocrine practice, 2018-09, Vol.24 (9), p.780-788 |
| issn | 1530-891X 1934-2403 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2084914802 |
| source | MEDLINE; ProQuest Central UK/Ireland; Alma/SFX Local Collection |
| subjects | Biopsy, Fine-Needle Cellular biology Cost analysis Cost-Benefit Analysis Gene expression Health Care Costs Histopathology Humans Medical diagnosis Mutation Retrospective Studies Surgery Thyroid cancer Thyroid Nodule - diagnosis Thyroid Nodule - genetics Thyroid Nodule - surgery Thyroidectomy Tumors |
| title | ThyroSeq ® V2.0 Molecular Testing: A Cost-Effective Approach for the Evaluation of Indeterminate Thyroid Nodules |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T17%3A18%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ThyroSeq%20%C2%AE%20V2.0%20Molecular%20Testing:%20A%20Cost-Effective%20Approach%20for%20the%20Evaluation%20of%20Indeterminate%20Thyroid%20Nodules&rft.jtitle=Endocrine%20practice&rft.au=Rivas,%20Ana%20Marcella&rft.date=2018-09&rft.volume=24&rft.issue=9&rft.spage=780&rft.epage=788&rft.pages=780-788&rft.issn=1530-891X&rft.eissn=1934-2403&rft_id=info:doi/10.4158/EP-2018-0212&rft_dat=%3Cproquest_cross%3E2084914802%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2120109770&rft_id=info:pmid/30084677&rfr_iscdi=true |